Opioid use in the United States has reached epidemic proportions.
1 Although deaths from opioid overdose
2,3 have captured the world’s attention, the endocrine complications of chronic opioid use have remained underappreciated. All opioid medications, especially long-acting opioids, suppress testosterone levels, often into the severely hypogonadal range.
4,5 Prescription opioid use has been shown to have an association with testosterone deficiency; nearly 20% of testosterone prescriptions written in the Veterans Health Administration (VHA) system were for men who were opioid users.
6 Testosterone deficiency among opioid users is associated with increased risk of sexual dysfunction, osteoporosis, and bone fractures.
7 However, to our knowledge, no data exist on major health outcomes in opioid users who are hypogonadal and either receive or do not receive testosterone treatment.